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ABSTRACT 
Objective: Familial adenomatous polyposis (FAP) also known as familial polyposis coli, is a hereditary disease characterized by progressive 
appearance of numerous polyps mainly in the large intestine. Polyps are initially benign but can easily become cancerous and as such it is a life 
threatening condition. Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor is thought to induce cell death, and thus prevent or delay the growth of 
polyps. So in the present study celecoxib loaded microspheres were prepared using control release Hydroxy propyl methyl cellulose (HPMC K4M) 
and pH dependent polymer eudragit L 100-55 in different ratios (1:1 to 1:4) respectively. The main objective of the study is to identify the polymer 
concentration required to prevent the drug release in stomach region and promotes in intestinal region. 
Methods: Emulsification solvent evaporation method was selected for the preparation and all the optimized formulations were evaluated for drug-
polymer interactions, percentage yield, micrometric properties, entrapment efficiency, particle size analysis, differential scanning calorimetry and 
in vitro dissolution study. 
Results: Drug and polymer interactions were evaluated by using FTIR and DSC. The FTIR spectrum and DSC thermograms stated that drug and 
polymer are compatible to each other. The micrometric properties of drug loaded microspheres were carried out and they were found to be as the 
angle of repose (18.26 °-40.69 °), bulk density (0.2846-0.3875), tapped density (0.4111-0.5428), Carr’s index (9.66-14.77), Hausner’s ratio (1.112-
1.2642) which were within the limits. In vitro dissolution, drug release was found to be from 4.5 to 6.5 h for the prepared four formulations (F1–F4). 
From the kinetic data modeling the order of drug release was found to be zero order and korsmeyer-peppas with n value above 0.5 for all the 
formulations indicating non-fickian diffusion.  
Conclusion: All the result demonstrated that celecoxib microspheres can be effectively used in the treatment of familial adenomatous polyposis 
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Familial Adenomatous Polyposis (FAP), also known as familial 
polyposis coli, is a hereditary disease characterized by the 
progressive appearance of numerous polyps mainly in the large 
intestine especially in children. FAP may lead to cancer of the large 
intestine, and as such is a life-threatening condition. The opted 
therapy for this disease is endoscopic surveillance with the removal 
of polyps when required and use of anti-inflammatory agent like 
celecoxib which is thought to induce cell death, and thus prevents or 
delay the growth of polyps [1]. The better therapy for FAP is use site 
specific release systems which offers advantages like prevention of 
side effects of drugs on healthy tissues and enhancement of the 
uptake of the drug by targeted cells. Enhancing of drug uptake by 
specific cells not only permits the internalization of substances with 
low cellular permeability but also allow for the maintenance of low 
blood to cell concentration ratio thereby reducing therapy limiting 
side effects. The successful delivery of drugs to the colon via the 
gastrointestinal tract requires the protection of drug from being 
released in the stomach and small intestine. This might be achieved 
by the use of special drug delivery system that can protect the drug 
during its transfer to required site. Targeting relies on exploiting a 
unique feature of the intended site and protecting the active agent 
until it reaches that site and this is achieved with the use of a 
combination of pH dependent and controlled release polymer [2]. 
Microspheres are small, solid and free-flowing particulate carriers 
containing dispersed drug particles either in solution or crystalline 
form that allow a sustained release or multiple release profiles of 
treatment with various active agents without major side effects and 
ideally having a particle size less than 200μm. They are prepared in 
such a way that the incorporated drug is delivered at the target site 
while reducing side effects by keeping systemic circulation low. The 
risk of dose dumping also seems to be considerably lower than with 
single unit dosage form. Microspheres allow the administration of 
smaller doses that are normally required and this reduces local 
irritation when compared to single unit dosage forms [3-6]. 
Considering an advantage of microspheres, the present investigation 
was undertaken to prepare and evaluate celecoxib loaded 
microspheres with enteric polymers like eudragit and a rate 
controlling polymer like HPMC K4M in different ratios so that the 
release of drug at gastric region is prevented with the use of ph 
dependent eudragit polymer and release of drug at controlled level is 
achieved with HPMCK4M. 
MATERIALS AND METHODS 
Materials 
Celecoxib, HPMC K4M, Eudragit L 100-55, Acetone, Alcohol, Dibutyl 
phthalate, Span 80, Liquid paraffin, Petroleum ether. 
Method 
For the preparation of celecoxib microspheres, emulsification solvent 
evaporation method opted. HPMC K4M and Eudragit L 100-55 in 
different ratios were dissolved in ethanol (S1) and acetone (S2) in 1:2 
ratio to form a homogeneous polymer solution. Celecoxib was added into 
the polymer solution and mixed thoroughly. Plasticizer (dibutyl 
phthalate 3% w/v) was added to above solution. The above organic 
phase was slowly poured at 30 °C into liquid paraffin (15 ml) containing 
varying concentrations of span 80 while stirring speed maintained at 
2000 rpm to form a smooth emulsion and stirring was continued until 
residual acetone and ethanol were evaporated and smooth walled, rigid 
and discrete microspheres were formed. The microspheres were 
collected by decantation and the product was washed with petroleum 
ether three times and dried at room temperature for 3 h.  
The microspheres were stored in a dessicator over fused calcium 
chloride for further use. Total twelve trial formulations were carried out 
[7. From that four main formulations were formulated with optimized 
span concentration. The detailed composition of the various 
formulations prepared are mentioned in below table 1 and table 2. 
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Table 1: Details of trial formulations prepared 
Formulation code Polymer ratio HPMC: eudragit S1 (ml) S2 (ml) Span concentration (%) 
TF1 1:1 5 10 1.2 
TF2 1:2 5 10 1.2 
TF3 1:3 5 10 1.2 
TF4 1:4 5 10 1.2 
TF5 1:1 5 10 1.0 
TF6 1:2 5 10 1.0 
TF7 1:3 5 10 1.0 
TF8 1:4 5 10 1.0 
TF9 1:1 5 10 0.8 
TF10 1:2 5 10 0.8 
TF11 1:3 5 10 0.8 
TF12 1:4 5 10 0.8 
 
Table 2: Design of main formulations 
Formulation code Drug (mg) Polymer ratio HPMC: eudragit Span concentration (%) 
F1 100 1:1 1% 
F2 100 1:2 1% 
F3 100 1:3 1% 
F4 100 1:4 1% 
 
Evaluation 
Drug-polymer interactions (FTIR study) 
FTIR spectroscopy of drug, polymers and physical mixture was 
performed using fourier transform infrared spectrophotometer 
(BRUKER, ALPHA). The sample was taken and by using potassium 
bromide, pellets were prepared using hydraulic pellet press and the 
spectrum was taken. 
Percentage yield 
The dried microspheres were collected and weighed. The actual weight 
of obtained microspheres divided by the total amount of all material that 
was used for the preparation of the microspheres gives percentage yield 
and it can be calculated using the following formula [8]. 
% Yield= (
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Micromeritic properties of microspheres 
The flow properties of the microspheres were investigated by 
determining the angle of repose, bulk density, tapped density, carr’s 
index, hausner’s ratio. The angle of repose was determined by the 
fixed–based funnel method. Bulk and tapped density were measured 
in 10 ml of the graduated cylinder. The cylinder was tapped from a 
height of 2 inches until a constant volume was obtained. The volume 
occupied by the sample after tapping was recorded and 
subsequently, bulk density, tapped density, carr’s index and 
hausner’s ratio was calculated [5]. 
The angle of repose was determined using the formula:  





Microspheres containing the equivalent to 50 mg of drug was 
allowed to equilibrate in 100 ml of phosphate buffer pH 6.8 for 24 h. 
The solution was filtered using whatmann filter paper. The resulting 
solution was analysed using a UV spectrometric method at 255 nm 
in the presence of blank prepared from microspheres containing all 






 x 100 
Particle size analysis 
Particle size analysis of drug-loaded microspheres was by optical 
microscopy (Olympus Model Szx-12). A small amount of 
microspheres was suspended in purified water (10 ml). Mount the 
sample on a clean glass slide and placed it on mechanical stage of the 
microscope. The eye piece of a microscope fitted with a micrometre 
by which the size of the spheres could be determined. The process 
was repeated for each batch of prepared microspheres. 
Differential scanning calorimetry 
DSC studies were performed using a universal V4.5A TA instruments. 
Accurately weighed samples (about 3 mg) were placed in a sealed 
aluminium pan, before heating under nitrogen flow (20 ml/min) at a 
scanning rate 20 °C/min from 40 to 300 °C. An empty aluminium pan 
was used as reference. DSC thermograms of pure substances, their 
physical mixtures and drug loaded microspheres were recorded. 
In vitro drug release study 
In vitro drug release study of microspheres was performed in pH 
progression medium at 37 °C±0.5 °C. The drug dissolution test of 
microspheres was performed by the basket method (USP dissolution 
apparatus type-I, LABINDIA DISSO 8000). Microspheres that are 
equivalent to 50 mg were weighed accurately and placed in the 
basket setup which is in 900 ml of dissolution medium and test was 
carried out in pH 1.2 buffer for 2 h using 0.1N HCl. After 2 h, the 
dissolution medium was replaced with phosphate buffer pH 6.8 and 
maintained up to 6 h. The samples were withdrawn from the 
dissolution medium at various time intervals using a syringe the rate 
of drug release was analyzed using UV-Visible spectrophotometer. 
RESULTS AND DISCUSSION 
Out of the twelve trial formulations with varying span 
concentrations (1.2%, 1%, 0.8 %), an optimum span concentration 
of 1% was chosen and four main formulations were formulated by 
incorporation of the drug. The resultant formulations with varying 
sizes were obtained as shown in fig. 1. 
Standard calibration 
Calibration of pure celecoxib was carried out in pH 1.2 buffer and 
phosphate buffer pH 6.8. The wavelength maxima was found to be 
255 nm for the drug. The calibration curves for celecoxib in 1.2 and 
6.8 pH buffers were given in fig. 2 and fig. 3 respectively. 
Drug-polymer interactions (FTIR study) 
The compatibility between the drug and the selected polymers were 
evaluated using FT–IR peak matching method. The IR spectra of pure 
drug, individual polymers and final formulation were shown in the fig. 
4, 5, 6 and 7 respectively. The standard peaks 1159 cm-1is due to S=O 
stretching, 3338 cm-1by NH2 stretching and 1563 cm-1by N-H 
stretching. There was no appearance or disappearance of peaks in the 
formulation, which confirmed the absence of chemical interaction 
between drug and polymers. 
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Fig. 1: Images of different prepared formulations F1-F4 
 
 
Fig. 2: Standard calibration curve of celecoxib in pH 1.2 buffer 
 
 
Fig. 3: Standard calibration curve of celecoxib in phosphate buffer pH 6.8 
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Fig. 4: FTIR spectrum of celecoxib 
 
 
Fig. 5: FTIR spectrum of HPMC K4M 
 
 
Fig. 6: FTIR spectrum of eudragit L 100-55 
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Fig. 7: FTIR spectrum of formulation 
 
Micromeritic properties of prepared microspheres 
Micromeritic studies like the determination of the angle of repose, bulk 
and tapped densities, compressibility index and hausner’s ratio were 
performed for all the four main formulations and the results were 
reported in table 3. 
Percentage yield and entrapment efficiency 
Percentage yield and entrapment efficiency for all the four main 
formulations containing drug were determined and reported in the 
table 4. 
Particle size analysis 
All the main formulations were observed under Olympus imaging 
binocular microscope and particle size was determined. The average 
size and standard deviations were given in table 5 and the images 
were shown in fig. 8. 
In vitro drug release studies 
In vitro drug release was studied by in vitro dissolution test carried 
out using basket apparatus. 
Prior to dissolution, in order to know about the stability of the 
microspheres at gastric pH, a study was conducted to determine 
the enteric capacity of the polymer, where the formulation was 
equally weighed and placed in 100 ml of each pH 1.2 buffer and 
phosphate buffer pH 6.8 for 2 h and it was observed that the 
microspheres in the beaker with pH 1.2 buffer as the medium 
remained as such where as those in beaker with phosphate 
buffer pH 6.8 were dissolved gradually as the time prolonged. 
They are shown in fig. 11. As the concentration of eudragit was 
increased the drug release in acidic pH was found to be reduced 
and the the presence of HPMC made the prolonged release up to 
6 h. 
 
Table 3: Micromeritic properties of drug loaded microspheres 
Batch Angle of repose ( °)  Bulk density (gm/cm3) Tapped density (gm/cm3) Carr’s index (%) Hausner’s ratio 
F1 14.26 °  0.3875 0.4428 9.66 1.112 
F2 16.69 °  0.3208 0.4277 11.99 1.1632 
F3 19.25 °  0.38 0.5428 12.99 1.2184 
F4 22.0 °  0.2846 0.4111 14.77 1.2642 
 
Table 4: Percentage yield and entrapment efficiency 
Formulation code Percentage yield Entrapment efficiency 
F1 62.5%  68.52 % 
F2 69.0 %  76.25 % 
F3 74.28 %  81.46 % 
F4 65.0 %  84.36% 
 
Table 5: Particle size analysis data 
S. No. Formulation code Average minimum radius(µ) Average maximum radius (µ) Average circle diameter (µ) 
01 F1 1.0618±1.6051 1.712±2.0072 5.5312±7.4666 
02 F2 3.7245±3.7752 4.6474±3.9243 14.322±10.536 
03 F3 1.7612±1.3127 3.2710±2.5049 8.5150±5.9215 
04 F4 2.7088±2.9990 2.8715±2.9026 10.613±11.114 
Values shown in the table indicates mean±standard devoation for n=3 
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Fig. 8: Images from olympus binocular microscope of all four main formulations 
 
 
Fig. 9: Thermogram of celecoxib 
 
 
Fig. 10: Thermogram of celecoxib final formulation 
 
 
Fig. 11: Fate of micro spheres in two buffers 
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Kinetic treatment of data 
The prepared formulations were subjected to dissolution study and 
the obtained data were fitted into different kinetic modelling to 
identify the drug release model and mechanism. The comparative 
dissolution data and kinetic data was given in the 7. Graphs were 
plotted for drug release and it was shown in the fig. 12. 
 
Table 7: Kinetic modeling data 
Formul-ation Zero order plot First order plot Higuchi plot Korsemeyer peppas plot 
K0 R2 r K1 R2 r KH R2 r n R2 r 
F1 18.21 0.931 0.972 0.4928 0.5081 0.9648 34.61 0.7265 0.866 0.8664 0.9833 1.737 
F2 10.42 0.996 0.998 0.4157 0.9659 0.9652 21.66 0.8807 0.9508 0.9847 0.9895 1.0531 
F3 12.09 0.952 0.9800 0.1870 0.9023 0.9980 24.94 0.789 0.9097 0.6868 0.8411 1.6108 
F4 13.09. 0.922 0.9642 0.2358 0.8994 0.9800 28.31 0.777 0.9062 0.4723 0.6781 1.954 
 
 
Fig. 12: Zero order plot for the formulations F1–F4 
 
CONCLUSION 
Documentation of adverse side effects of systemically delivered 
celecoxib envisaged the development of a formulation that could 
deliver the drug to the defined site. Studies have proven that local 
application of celcoxib is postulated to be advantageous over 
systemic circulation in the context of FAP for chemoprevention of 
cancer onset [9]. The current study data implies that microspheres 
containing celecoxib can be formulated by emulsification solvent 
evaporation technique by using HPMC K4M and eudragit L 100-55 as 
polymers, alcohol and acetone as solvents, span 80 as a surfactant 
and dibutyl phthalate as a plasticizer. The I. R. spectra and DSC 
thermograms revealed that there was no interaction between 
polymers and drug. All the polymers used were compatible with the 
drug. The prepared microspheres were strong spherical with 
narrow size distributions could be prepared with high yields and 
good entrapment efficiencies. By increase in the percentage of 
polymer concentrations significantly affected on the size of spheres 
i.e. a gradual increase in the size of spheres and the optimum release 
of celecoxib in the intestinal region was achieved. 
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